This was demonstrated by studying a familial AD mutation known to enhance APP-CTFs production and by pharmacological blockade of γ-secretase that increases APP-CTFs recovery and impairs Aβ and AICD productions as well as by the study of models overexpressing C99 fragment. The gene discussed is APP; the disease is Alzheimer disease.